Table 2.
Clinical trials for assessing the effect of oncolytic reovirus, parvovirus, and vaccinia virus therapy in patients suffering from pancreatic cancer.
| Phase | Oncolytic virus | Site of Admin | Combined with | No of Patients | Patients’ Info | Year | mPFS (Months) | mOS (Months) | Study |
|---|---|---|---|---|---|---|---|---|---|
| Reovirus | |||||||||
| II | REOLYSIN | intravenous injection | Carboplatin/Paclitaxel | 73 | Arm A: 36 Carboplatin + Paclitaxel + Reolysin Arm B: 37 Carboplatin + Paclitaxel |
Start: 2010 End: 2016 |
Arm A: 4.9 Arm B: 5.2 |
Arm A: 7.3 Arm B: 8 |
(NCT01280058) (180) |
| II | REOLYSIN | Intravenous injection | Gemcitabine | 34 | LAPC or metastatic | Start: 2009 End: 2015 |
3.4 | 10.2 | (NCT00998322) (181) |
| I | REOLYSIN | Intravenous injection |
Gemcitabine/ Irinotecan/ Leucovorin/ 5-fluorouracil/ Pembrolizumab |
11 | Advanced or metastatic | Start: 2015 End: 2018 |
2.0 | 3.1 | (NCT02620423) (182) |
| Parvovirus | |||||||||
| II | ParvOryx | Intravenous and Intratumoral injection | Gemcitabine Started after 28 days of H-1PV first dose | 7 | Unresectable LAPC with at least one hepatic metastasis |
Start: 2015 End: 2018 |
3.4 | 5.8 | (NCT02653313) (183, 184) |
| Vaccinia virus | |||||||||
| I | VV expressing p53 |
Subcutaneous injection | – | 12 5 pancreatic cancer Patients 16 |
Unresectable and chemotherapy resistant or recurrent tumors | Start: 2011 End: 2013 |
– | – | (NCT01191684) (185) |
| I | vvDD | Intratumoral injection | – | 2 Pancreatic cancer Patients |
Advanced solid tumors | Study End: 2014 |
– | – | (186) |